>
Market Cap | Β£n/a |
Enterprise Value | Β£n/a |
Revenue | Β£n/a |
Position in Universe | th / 1821 |
Industry | Market | |
---|---|---|
|
|
|
|
|
|
|
|
Year End 01st Jan | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
---|---|---|---|---|---|---|---|---|---|---|
0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
x
|
||||||||||
Profitability | ||||||||||
%
|
||||||||||
%
|
||||||||||
%
|
||||||||||
Cashflow | ||||||||||
Dividends | ||||||||||
Balance Sheet | ||||||||||
m
|
||||||||||
m
|
||||||||||
m
|
||||||||||
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing % | |||
Net Gearing % | |||
Cash / Assets % |
Liquidity (ttm) | ||
---|---|---|
Curr. Ratio | ||
Quick Ratio | ||
Interest Cov. |
Efficiency (ttm) | ||
---|---|---|
Asset Turnover | ||
Recs Turnover | ||
Stock Turnover |
Latest interim period vs. prior period | Industry | Market |
---|---|---|
|
|
|
|
|
3yr Compound Annual Growth Rate | Industry | Market |
---|---|---|
|
|
|
|
|
|
|
|
Redx Pharma Plc, is engaged in drug discovery, pre-clinical development and licensing. It is engaged in drug discovery across cancer, infection and autoimmune diseases. It has over three programs like Porcupine RXC004 is a combination with PD-1 / PD-L1 in solid tumor (colorectal cancer), GI-targeted ROCK is focused on Crohnβs disease, Porcupine (REDX06109) is focused on Idiopathic pulmonary fibrosis (IPF), ROCK2 selective is focused on Non-alcoholic Steatohepatitis (NASH) and research in Validated targets (SHP2, AZ collaboration and undisclosed targets) focused in Cancer & Fibrosis which has reached candidate nomination stage. Its anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX004, is a class of antibiotic acting through the type II bacterial topoisomerases.
Last Annual | January 1st, 1970 |
Last Interim | January 1st, 1970 |
Incorporated | September 7, 2010 |
Public Since | March 27, 2015 |
No. of Shareholders: | n/a |
No. of Employees: | 52 |
Sector | Healthcare |
Industry | Biotechnology & Medical Research |
Index | |
Exchange | London Stock Exchange |
Shares in Issue | |
Free Float | (0.0%) |
Eligible for |
×
ISAs
✓
SIPPs
|
Address | Block 33 Mereside Alderley Park, MACCLESFIELD, SK10 4TG, United Kingdom |
Web | https://www.redxpharma.com/ |
Phone | +44 151 7064747 |
Contact | () |
Auditors | RSM UK Audit LLP |